Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Furkejuvvon:
Váldodahkkit: | , , , , , , , , , , , , , |
---|---|
Materiálatiipa: | Artihkal |
Giella: | eaŋgalasgiella |
Almmustuhtton: |
Philipps-Universität Marburg
2023
|
Fáttát: | |
Liŋkkat: | PDF-ollesdeaksta |
Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Interneahtta
PDF-ollesdeakstaHildobáiki: |
urn:nbn:de:hebis:04-es2024-04361 |
---|---|
Almmustuhttinbeaivi: |
2024-01-17 |
Gáldu: |
Erstveröffentlichung: Horvath, D., Temperton, N., Mayora-Neto, M. et al. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice. Sci Rep 13, 4648 (2023). https://doi.org/10.1038/s41598-023-31198-3 |
Downloads: |
9 (2024) |
Lizenz: |
https://creativecommons.org/licenses/by/4.0 |
Liŋka materiálii: |
https://archiv.ub.uni-marburg.de/es/2024/0436 https://doi.org/10.1038/s41598-023-31198-3 |